Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice

Experimental Neurology

Volumn 199, Issue 2, 2006, Pages 265-273

  Pedersen, Ward A ^a   McMillan, Pamela J ^b,d   Kulstad, J Jacob ^b,e   Leverenz, James B ^c,d,e   Craft, Suzanne ^b,d   Haynatzki, Gleb R ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c Education   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Glucocorticoids; Insulin resistance; Insulin degrading enzyme; Metyrapone; Peroxisome proliferator activated receptor ; Stress; Thiazolidinedione

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BRAIN ENZYME; CORTICOSTERONE; GLUCOCORTICOID; MESSENGER RNA; METYRAPONE; ROSIGLITAZONE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BEHAVIOR; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DIET RESTRICTION; DRUG EFFECT; ENZYME DEGRADATION; INSULIN METABOLISM; INSULIN RESISTANCE; LEARNING; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPATIAL DISCRIMINATION; TISSUE LEVEL; WILD TYPE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CORTICOSTERONE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC AGENTS; IN SITU HYBRIDIZATION; INSULYSIN; LEARNING DISORDERS; MALE; MEMORY DISORDERS; METYRAPONE; MICE; MICE, TRANSGENIC; THIAZOLIDINEDIONES;

EID: 33745234766     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.01.018     Document Type: Article

References (45)

1. Andrews R.C., and Walker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin. Sci. 96 (1999) 512-523
2. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., and Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61 (2004) 661-666
3. Burén J., Liu H.X., Jensen J., and Eriksson J.W. Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur. J. Endocrinol. 146 (2002) 419-429
4. Calle C., Campion J., Garcia-Arencibia M., Maestro B., and Davila N. Transcriptional inhibition of the human insulin receptor gene by aldosterone. J. Steroid Biochem. Mol. Biol. 84 (2003) 543-553
5. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Lee-Way J., Kovacina K.S., and Craft S.C. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele. Am. J. Pathol. 162 (2003) 313-319
6. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., and Porte Jr. D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50 (1998) 164-168
7. Craft S., Asthana S., Schellenberg G., Cherrier M., Baker L.D., Newcomer J., Plymate S., Latendresse S., Petrova A., Raskind M., Peskind E., Lofgreen C., and Grimwood K. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70 (1999) 146-152
8. Farris W., Mansourian S., Leissring M.A., Eckman E.A., Bertram L., Eckman C.B., Tanzi R.E., and Selkoe D.J. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am. J. Pathol. 164 (2004) 1425-1434
9. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., and Xu H. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21 (2001) 2561-2570
10. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am. J. Cardiol. 90 (2002) 3G-10G (suppl.)
11. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., and Landreth G.E. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
12. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., and Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004) 902-904
13. Hoyer S., Lee S.K., Loffler T., and Schliebs R. Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease?. Ann. N. Y. Acad. Sci. 920 (2000) 256-258
14. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., and Saido T.C. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6 (2000) 143-150
15. Joels M., and Vreugdenhil E. Corticosteroids in the brain. Cellular and molecular actions. Mol. Neurobiol. 17 (1998) 87-108
16. Kamboh M.I. Molecular genetics of late-onset Alzheimer's disease. Ann. Hum. Genet. 68 (2004) 381-404
17. Kellendonk C., Gass P., Kretz O., Schutz G., and Tronche F. Corticosteroid receptors in the brain: gene targeting studies. Brain Res. Bull. 57 (2002) 73-83
18. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., and Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22 (2002) 6331-6335
19. Kulstad J.J., McMillan P.J., Leverenz J.B., Cook D.G., Green P.S., Peskind E.R., Wilkinson C.W., Farris W., Mehta P.D., and Craft S. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J. Neuropathol. Exp. Neurol. 64 (2005) 139-146
20. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., Kervinen K., Kesaniemi Y.A., Riekkinen P.J., and Laakso M. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br. Med. J. 315 (1997) 1045-1049
21. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O'Brien P.C., and Palumbo P.J. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 145 (1997) 301-308
22. Leissring M.A., Lu A., Condron M.M., Teplow D.B., Stein R.L., Farris W., and Selkoe D.J. Kinetics of amyloid β-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem. 278 (2003) 37314-37320
23. Luchsinger J.A., Tang M.X., Stern Y., Shea S., and Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 154 (2001) 635-641
24. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63 (2004) 1187-1192
25. McEwen B.S. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann. N. Y. Acad. Sci. 933 (2001) 265-277
26. Mizoguchi K., Yuzurihara M., Ishige A., Sasaki H., Chui D.H., and Tabira T. Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J. Neurosci. 20 (2000) 1568-1574
27. Mizoguchi K., Ishige A., Takeda S., Aburada M., and Tabira T. Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. J. Neurosci. 24 (2004) 5492-5499
28. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., and Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 (1999) 1937-1942
29. Pedersen W.A., and Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 17 (2004) 500-506
30. Pedersen W.A., Culmsee C., Ziegler D., Herman J.P., and Mattson M.P. Aberrant stress response associated with severe hypoglycemia in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 13 (1999) 159-165
31. Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256-1262
32. Perez A., Morelli L., Cresto J.C., and Castano E.M. Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 25 (2000) 247-255
33. Peskind E.R., Wilkinson C.W., Petrie E.C., Schellenberg G.D., and Raskind M.A. Increased CSF cortisol in AD is a function of APOE genotype. Neurology 56 (2001) 1094-1098
34. Pomara N., Greenberg W.M., Branford M.D., and Doraiswamy P.M. Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update. Psychopharmacol. Bull. 37 (2003) 120-134
35. Qiu W.Q., Ye Z., Kholodenko D., Seubert P., and Selkoe D.J. Degradation of amyloid β-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272 (1997) 6641-6646
36. Roozendaal B., Phillips R.G., Power A.E., Brooke S.M., Sapolsky R.M., and McGaugh J.L. Memory retrieval impairment induced by hippocampal CA3 lesions is blocked by adrenocortical suppression. Nat. Neurosci. 4 (2001) 1169-1171
37. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 (2001) 177-180
38. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., and de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J. Alzheimer's Dis. 7 (2005) 63-80
39. Wagstaff A.J., and Goa K.L. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62 (2002) 1805-1837
40. Watson G.S., and Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease. CNS Drugs 17 (2003) 27-45
41. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958
42. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin G.A., and Ashe K.H. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22 (2002) 1858-1867
43. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., and Landreth G. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23 (2003) 7504-7509
44. Zhao W.Q., Chen H., Quon M.J., and Alkon D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490 (2004) 71-81
45. Zhao L., Teter B., Morihara T., Lim G.P., Ambegaokar S.S., Ubeda O.J., Frautschy S.A., and Cole G.M. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J. Neurosci. 24 (2004) 11120-11126